Inventor
TU NAXIN
US34 patents
⚠️ This page may combine multiple inventors who share the name “TU NAXIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
31 patentsUS8847005B2Sep 30, 2014
Genetically modified major histocompatibility complex mice
REGENERON PHARMA33 citations98
US9113616B2Aug 25, 2015
Genetically modified mice having humanized TCR variable genes
REGENERON PHARMA67 citations97
US9043996B2Jun 2, 2015
Genetically modified major histocompatibility complex animals
REGENERON PHARMA31 citations94
US9089599B2Jul 28, 2015
Low affinity FCGR deficient mice
REGENERON PHARMA9 citations93
US9056130B2Jun 16, 2015
Humanized Fc gamma R mice
REGENERON PHARMA9 citations93
US10542735B2Jan 28, 2020
Humanized non-human animals with restricted immunoglobulin heavy chain loci
REGENERON PHARMA6 citations84
US10426848B2Oct 1, 2019
Humanized FcγR mice
REGENERON PHARMA3 citations84
US9848587B2Dec 26, 2017
Humanized T cell co-receptor mice
REGENERON PHARMA6 citations84
US9687566B2Jun 27, 2017
Low affinity FCGR deficient mice
REGENERON PHARMA6 citations84
US9585373B2Mar 7, 2017
Genetically modified major histocompatibility complex mice
REGENERON PHARMA8 citations84
US9474255B2Oct 25, 2016
Non-human animals having humanized Fc-gamma receptors
REGENERON PHARMA6 citations84
US9221894B2Dec 29, 2015
Isolated cells from humanized FcγR mice
REGENERON PHARMA9 citations84
US11528895B2Dec 20, 2022
Genetically modified T cell receptor mice
REGENERON PHARMA2 citations73
US11219195B2Jan 11, 2022
Genetically modified major histocompatibility complex mice
REGENERON PHARMA1 citations73
US11020495B2Jun 1, 2021
Humanized low affinity FCγR mouse cells
REGENERON PHARMA2 citations73
US10986822B2Apr 27, 2021
Genetically modified major histocompatibility complex mice
REGENERON PHARMA1 citations73
US10820581B2Nov 3, 2020
Humanized T cell co-receptor mice
REGENERON PHARMA1 citations73
US10555507B2Feb 11, 2020
Non-human animals having humanized Fc-gamma receptors
REGENERON PHARMA1 citations73
US10219493B2Mar 5, 2019
Genetically modified major histocompatibility complex mice
REGENERON PHARMA1 citations73
US10820582B2Nov 3, 2020
Non-human animals having an engineered immunoglobulin Λ light chain locus
REGENERON PHARMA3 citations71
US12063915B2Aug 20, 2024
Humanized T cell co-receptor mice
REGENERON PHARMA0 citations63
US12036288B2Jul 16, 2024
Methods of using humanized FCγR mice to assay Fc regions
REGENERON PHARMA0 citations63
US11503812B2Nov 22, 2022
Non-human animals having humanized Fc-gamma receptors
REGENERON PHARMA0 citations63
US12582105B2Mar 24, 2026
Genetically modified T cell receptor mice
REGENERON PHARMA0 citations62
US11576984B2Feb 14, 2023
Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
REGENERON PHARMA1 citations62
US12433264B2Oct 7, 2025
Non-human animals having an engineered immunoglobulin lambda light chain locus
REGENERON PHARMA0 citations61
US12295354B2May 13, 2025
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
REGENERON PHARMA0 citations61
US10980221B2Apr 20, 2021
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
REGENERON PHARMA0 citations61
US9700025B2Jul 11, 2017
Genetically modified major histocompatibility complex animals
REGENERON PHARMA1 citations52
US12376573B2Aug 5, 2025
Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire
REGENERON PHARMA0 citations50
US11186848B2Nov 30, 2021
Non-human animals expressing humanized C1Q complex
REGENERON PHARMA0 citations50